Inpharma Weekly

, Volume 1200, Issue 1, pp 11–12 | Cite as


leaving the flu out in the cold?
  • Carmen Innes
Newsletter Article


Zanamivir [‘Relenza’] is an exciting new neuraminidase inhibitor indicated for the treatment of influenza virus infection. Data from a pooled analysis of 6 randomised controlled trials show that zanamivir is of most benefit in patients aged ≥ 50 years and in those with severe influenza symptoms. This analysis, and another study showing that zanamivir reduces loss of productivity by preventing influenza, were presented at the 21st International Congress on Chemotherapy [ Birmingham, UK; July 1999 ].


Influenza Placebo Recipient Pool Analysis Amantadine Zanamivir 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Adis International Ltd 1999

Authors and Affiliations

  • Carmen Innes

There are no affiliations available

Personalised recommendations